Acute childhood leukemia 1. Clinical risk grouping tends to be consistent Clinical (age of onset and total number of initial leukocytes), MIMC is the consensus; 2. Early treatment response (prednisone induction test, 15-19 days bone marrow naïve cells less than 5%, 28-35 days whether complete remission), as prognosis assessment and adjustment of treatment response; 3. 28-35 days bone marrow MRD decreased to 10-4 Below, good prognosis; 4, acute promyelocytic leukemia Because of the widespread use of retinoic acid and arsenic trioxide, the prognosis is significantly improved. 5, for the prognosis of children with biphenotypic leukemia is not significantly different from that of children with acute leukemia (AL) without serial crossover, and the same treatment regimen can be used for chemotherapy; 6, there is a certain degree of bone loss and bone resorption in leukemia; after treatment, because chemotherapeutic drugs may have side effects on bone metabolism, inhibiting bone synthesis and promoting bone resorption. It is recommended to apply anti-osteoporosis agents during treatment to improve the quality of survival of children with leukemia; 7. AL itself and combined chemotherapy have no significant effect on pituitary gonadal axis function and growth hormone level in children; combined chemotherapy has no effect on thyroid function. Chemotherapy complications 1, G- bacteria accounted for 46.43%, G+ bacteria 28.57%, fungi 17.86%; 2, the top five bacteria: Escherichia coli, Pseudomonas aeruginosa, Candida albicans, Staphylococcus aureus, Staphylococcus epidermidis; 3, G- bacteria susceptibility antibiotics preferred imipenem, followed by cefoperazone / sulbactam; G+ susceptibility rate to vancomycin greater than 99%. 4. The levels of ultrasensitive C-reactive protein (hs-CR) and prostacyclin are significantly elevated, which is a clinical guideline for the early diagnosis and treatment of post-chemotherapy granular deficiency fever with sepsis. The problem of hematopoietic stem cell transplantation In acute promyelocytic leukemia, hematopoietic stem cell transplantation is not used as the treatment of choice. In addition, low-risk children with acute gonorrhea have high cure rates with chemotherapy alone, and hematopoietic stem cell transplantation is also used as a second-line treatment. For those patients with acute leukemia who are not eligible for allogeneic HSCT, autologous HSCT is an effective consolidation therapy after complete remission of acute leukemia.